Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Reproducible induction of the enzyme tyrosine aminotransferase by dibutyryl
cAMP
(Bt2cAMP) in a line of HTC
hepatoma
cells in suspension culture requires that the cells be preinduced with dexamethasone, a synthetic glucocorticoid which itself induces tyrosine aminotransferase. Concentrations of dexamethasone that do not induce tyrosine aminotransferase fail to support Bt2cAMP induction, removal of the steroid from the medium leads to a loss of the Bt2cAMP effect, and an HTC cell line whose aminotransferase is not steroid-inducible does not respond to the cyclic nucleotide. We show that the further induction of tyrosine aminotransferase by Bt2cAMP in dexamethasone-treated cells is due to an increased rate of enzyme synthesis. The cyclic nucleotide has no effect on aminotransferase synthesis in cells grown in the absence of steroid. Several lines of evidence suggest that dexamethasone acts at a step beyond the activation of protein kinase by
cAMP
: (a) basal levels of
cAMP
are not altered by growth of HTC cells in dexamethasone; (b) accumulation of
cAMP
from the medium is not enhanced; (c) the glucocorticoid does not induce cAMP-dependent protein kinase in HTC cells; and (d) there is no augmentation of
cAMP
binding to the regulatory protein, nor is there any change in
cAMP
activation of protein kinase caused by growth in dexamethasone. These results help define a system that should be useful in studying the interaction of cyclic nucleotides and steroid hormones.
...
PMID:Interaction of glucocorticoid hormones and cyclic nucleotides in induction of tyrosine aminotransferase in cultured hepatoma cells. 1 22
Adenylate cyclase activity as well as intracellular content of sAMP were decreased 2.5-4-fold, as compared with normal state, in plasmatic membranes (PM) of
hepatoma
22 and of Ehrlich ascites carcinoma--the tumors characterized by high level- of malignancy. Activity of
cAMP
phosphodiesterase exceeded distinctly the normal value in all the tumors studied. In less malignant
hepatoma
48 the adenylate cyclase activity and content of
cAMP
were similar to those found in normal liver cells. The guanylate cyclase activity did not differ markedly from values found in normal liver cells in PM of all the tumors studied and in liver tissue of the tumor-bearing animals. Distinct alterations were not found in content of cGMP in the tumors, except of hepatomas 60 and 22, in which the nucleotide level exceeded 2-fold the normal value. The ratio
cAMP
/cGMP was decreased in the most malignant tumors. At the same time, the ratio was distinctly elevated in tumors with the middle level of malignancy (hepatomas 60 and 61).
...
PMID:[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]. 3 Feb 12
In
Hepatoma
Tissue Culture (HTC) cells induction of tyrosine aminotransferase (TAT) by dibutyryl
cAMP
(DBcAMP) is regulated at some posttranscriptional step. In synchronized HTC cells TAT can be induced by DBcAMP in late G1 and in the S phase of the cell cycle only.
...
PMID:Induction of tyrosine aminotransferase by dibutyryl cyclic-AMP in synchronized hepatoma cells. 3 31
Epidermal growth factor stimulated both [3H]thymidine uptake and proliferation of rat AH66
hepatoma
cells. However, the increase in cell number was not accompanied by a proportional increase in the levels of alpha-fetoprotein of the culture media. The effects of EGF on the cell proliferation were antagonized by N6,O2'-dibutyryl
cAMP
.
...
PMID:Epidermal growth factor stimulates proliferation of rat hepatoma cells producing alpha-fetoprotein. 9 54
Normal rat liver cells (BRL-1) that respond to isoproterenol (beta+2), prostaglandin E1 (PGE+1) and adenosine (Ado+) with a rise in adenosine 3':5'-monophosphate (
cAMP
) content have been hybridized with rat
hepatoma
cells (H35) which do not respond to any of these agonists (beta-2, PGE-1 and Ado-). Both the initial hybrid line (BF5) and a subclone (BF5-1-1) expressed a beta+2, PGE+1, Ado- phenotype. However, full expression of the responsive phenotype in the BF5 line was apparent only if phosphodiesterase activity was blocked, for example, by methylisobutylxanthine (MIX). Direct measurements showed the rate of degradation of
cAMP
to be 7 times greater in intact BF5 cells than in the BRL-1 parent. In contrast to BF5 cells, the BF5-1-1 cells did not express maximal responsiveness to any of the agonists even in the presence of MIX. The differential accumulation of intracellular
cAMP
observed with BRL-1, BF5 and BF5-1-1 cells in response to isoproterenol was shown not to be as a result of differential rates of excretion of
cAMP
. Furthermore, no differences in the apparent affinities of the beta 2-catecholamine receptors for isoproterenol were observed. It is suggested that the increased degradative capacity of BF5 cells accounts for the difference in
cAMP
accumulation in these cells compared with the BRL-1 parent. The reduced responsiveness of BF5-1-1 cells, however, does not appear to be solely due to increased phosphodiesterase activity. It appears that the beta 2- phenotype may not always be dominant in hybrid crosses of this type as has been reported previously.
...
PMID:Expression of the regulation of cAMP metabolism in somatic cell hybrids. 9 76
Rat liver
cAMP
phosphodiesterase has been fractionated into four peaks of activity with isoelectrofocusing column chromatography. The major two liver peaks (high Km enzymes) decreased with increasing growth rate while the minor two liver peaks (low Km enzymes) increased in one fast growing Morris
hepatoma
. There was also less total phosphodiesterase activity in the fast growing
hepatoma
.
...
PMID:Cyclic AMP phosphodiesterase activity in three Morris hepatomas. 16 75
There is evidence than adenosine 3',5'-monophosphate (
cAMP
) and guanosine 3',5'-monophosphate (cGMP) may have antagonistic actions on cell growth, with
cAMP
inhibiting and cGMP stimulating this process. However, reductions in
cAMP
and increases in cGMP are not charactersitic of all neoplastic tissues. Thus, benign and malignant tissues from
hepatoma
-bearing rats exposed to the hepatic carcinogen DL-ethionine have elevated rather than depressed
cAMP
, compared to control liver, and parenteral administration of this drug increases hepatic
cAMP
within hours. In the present study, the effects of ethionine ingestion on the hepatic content and metabolism of both
cAMP
and cGMP were examined sequentially in rats at 2 and then 6 wk intervals, from the initiation of drug administration until the development of hepatomas. After 2 wk,
cAMP
content of quick-frozen liver from rats receiving ethionine (E) was significantly increased (826 +/- 91 pmole/g wet weight) above that of liver from pair-fed controls (C, 415 +/- 44), whether calculated by tissue wet weight, protein, or DNA content. In benign tissue from E, higher
cAMP
was still evident after in vitro incubations of slices with 2 mM 1-methyl-3-iso-butylxanthine (MIX) and was associated with enhanced adenylate cyclase and unchanged high or low Km
cAMP
-phosphodiesterase activities. These findings are compatible with accelerated
cAMP
generation in liver from E. Protein kinase activity ratios were significantly increased in frozen liver from E (0.52 +/- 0.04 versus 0.36 +/- 0.03 in C), and the percent glycogen synthetase in the I form was clearly reduced (19% +/- 2% in E versus 47% +/- 5% in c). incubation of hepatic slices from E or C with MIX and/or 10 muM glucagon further increased
cAMP
and protein kinase activity ratios, data which imply higher effective, as well as total, cellular
cAMP
in E. Changes in
cAMP
metabolism and action observed at 2 wk persisted throughout the 38-wk period of drug ingestion. Adenylate cyclase activity,
cAMP
content, and protein kinase activity ratios of ethionine-induced hepatomas exceeded those of both the surrounding liver from tumor-bearing rats and that of control liver, but alterations in these parameters were qualitatively similar in both tissues from E. By contrast, while cGMP in quick-frozen surrounding liver from tumor-bearing rats (36 +/- 4 pmole/g wet weight) did not differ from that of control liver (30 +/- 3), cGMP in the hepatomas was increased. This change was evident in both frozen tumor (89 +/- 10) and in tumor slices incubated in vitro with MIX (C, 90 +/- 11; surrounding liver, 85 +/- 10;
hepatoma
231 +/- 29). These results indicate that malignant conversion can occur in liver with a sustained elevation of both total and effective
cAMP
during the premalignant phase. The increase in cGMP detected in ethionine-induced hepatomas could also be a key determinant of malignant transformation in the model, although premalignant changes in cGMP were not apparent.
...
PMID:Sequential alterations in the hepatic content and metabolism of cyclic AMP and cyclic GMP induced by DL-ethionine: evidence for malignant transformation of liver with a sustained increase in cyclic AMP. 18 92
Plasma membranes from rat liver were found to contain at least two types of specific binding sites for cyclic [3H] adenosine 3', 5'-monophosphate (c[3H]AMP) with apparent dissociation constants of 0.51 +/- 0.14 and 2.9 +/- 0.6 nM (O degrees), respectively. The levels of these binding sites in liver plasma membranes were about 0.60 +/- 0.20 and 1.3 +/- 0.5 pmole/mg protein. The highest affinity binders for c[3H]AMP were found to be reduced in amount in plasma membranes of ascites hepatomas to 1/3 to 1/4 as compared with liver membranes in the cases of AH-130 and AH-7974 and to an almost undetectable level in the case of AH-130F(N). No difference in the endogenous phosphorylation of plasma membranes by (gamma-32P])ATP was, however, detected among liver and
hepatoma
plasma membranes. Addition of
cAMP
or cGMP at various concentrations did not affect the endogenous phosphorylation of plasma membranes of these cells.
...
PMID:High affinity binders for cyclic adenosine 3', 5'-monophosphate on plasma membranes isolated from rat liver and ascites hepatomas. 18 3
The studies are presented which demonstrate that smooth endoplasmic membrane of normal liver has a single apparent binding site for
cAMP
with a KD of 0.6 X 10(-8) M. In contrast to this, however, cyclic AMP binding to the intracellular membrane of
hepatoma
7800 exhibit two binding sites; the binding constant of one site on the tumor membrane is comparable to that of the normal liver whereas the value of the second intrinsic association constant differ by a factor of 10. It is suggested that there may be an association between abnormal cyclic nucleotide metabolism and the intracellular membrane modulation of the expression of genetic information in normal and neoplastic cells.
...
PMID:Cyclin nucleotide binding sites of the smooth endoplasmic reticulum from normal and neoplastic liver in the rat. 18 1
A substantial portion of the histone phosphorylating activity of bovine thymus chromatin can be isolated by extraction in 0.2 M NaCl. The specificity of this extract for either free histones or washed chromatin substrates was compared. The salt-extracted kinase enzymes favor H2b as the major acceptor when whole free histone is the substrate and H3 when the substrate is intact chromatin. The H3 kinase activity of bovine thymus tissue has been purified free from other detectable histone kinase activities by ammonium sulfate fractionation and is highly specific for H3 histone when assayed either with chromatin or isolated whole histone. The activity is
cAMP
-independent. Tryptic peptide mapping of the labeled H3 histone reveals a single site of phosphorylation. This site appears to be identical with the major site of metaphase-associated H3 phosphorylation in
hepatoma
tissue culture cells. No corresponding H3 phosphorylation has been detected in thymus tissue in vivo.
...
PMID:An H3 histone-specific kinase isolated from bovine thymus chromatin. 20 51
1
2
3
4
5
6
7
8
9
10
Next >>